Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how each company stacks up on ...

Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.

Three mid-cap biotechs have become prime acquisition targets, but only one offers what big pharma is hunting for most.

It has been a banner year for biotech buyouts, and these are two of the prime targets.

Biotech investors are finally getting something they haven't seen in years: a friendlier macro environment. Interest rates appear to be stabilizing, FDA activity is picking up again, and large ...

While investors have long treated the pharmaceuticals’ industry with caution, those that avoid the sector are missing out on clear opportunities. While navigating the fast-developing industry is not ...

Innovative Pharmaceutical Biotech (HK:0399) has released an update. Innovative Pharmaceutical Biotech Limited has entered into a Memorandum of Understanding to potentially acquire a majority stake in ...

Medicare’s new GLP-1 Bridge program boosts seniors’ access to weight-loss drugs through 2027—see top GLP-1 and biotech stocks to watch now.

Interview with the Chairman and CEO: MAIA Biotechnology Inc. (NYSEAMERICAN:MAIA) Vlad Vitoc Interview with the Chairman and CEO: Mira Pharmaceuticals, Inc. (NASDAQ:MIRA) and Telomir Pharmaceuticals, ...

DUBLIN--(BUSINESS WIRE)--The "Manufacturing and Supply Deals in Pharmaceuticals and Biotechnology 2020-2025" has been added to ResearchAndMarkets.com's offering. This report contains a comprehensive ...

They have at least one thing in common: An exciting pipeline.